)
Visual
test
Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) investor relations material
Guangzhou Baiyunshan Pharmaceutical Holdings Company Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary20 Mar, 2026
Executive summary
Operating revenue reached RMB77.66 billion in 2025, up 3.55% year-over-year; net profit attributable to shareholders was RMB2.98 billion, up 5.21% year-over-year.
The company maintained its leading position in modernized traditional Chinese medicine, chemical pharmaceuticals, natural beverages, and pharmaceutical commerce.
Major initiatives included strengthening the TCM and API businesses, expanding international presence, and advancing digital transformation.
R&D focused on oncology, chronic diseases, respiratory, immune, and men's health, with over 160 projects in the pipeline.
No significant events occurred that would impact ongoing operations; no risk of delisting.
Financial highlights
Operating revenue: RMB77.66 billion (+3.55% YoY); net profit attributable to shareholders: RMB2.98 billion (+5.21% YoY).
Total assets: RMB84.51 billion (+3.46% YoY); net assets attributable to shareholders: RMB37.79 billion (+5.25% YoY).
Basic EPS: RMB1.835 (+5.21% YoY); weighted average ROE: 8.09%.
Net cash flow from operating activities: -RMB232 million (down from +RMB3.44 billion in 2024).
Proposed cash dividend: RMB0.45 per share, totaling RMB731.6 million.
Outlook and guidance
2026 strategy focuses on quality and efficiency improvement, innovation, internationalization, and digital transformation.
Plans to increase R&D investment, accelerate product launches, and expand global market presence.
Capital expenditure for 2026 expected at RMB2.15 billion, mainly for production base construction and equipment upgrades.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Guangzhou Baiyunshan Pharmaceutical Holdings Company
- Revenue up 2.68% but net profit down 9.31% amid higher costs and negative cash flow.874
Q2 202410 Dec 2025 - Q3 2025 delivered strong profit growth and EPS, despite a sharp drop in operating cash flow.874Q3 202510 Dec 2025
- Revenue up 1.93% YoY, net profit down 1.31%, interim dividend RMB0.40 per share.874Q2 202511 Sep 2025
- Net profit fell 37.82% in Q3 2024 as sales and margins declined under macroeconomic pressures.874Q3 202413 Jun 2025
- Revenue and net profit declined in Q1 2025, with cash flow pressures intensifying.874Q1 20256 Jun 2025
- Net profit dropped 30% on flat revenue; 2025 focus is on supply chain and innovation.874Q4 20246 Jun 2025
Next Guangzhou Baiyunshan Pharmaceutical Holdings Company earnings date
Q1 202624 Apr, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company
Next Guangzhou Baiyunshan Pharmaceutical Holdings Company earnings date
Q1 202624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage